Tyrosine-based 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine and -adenine ((S)-HPMPC and (S)-HPMPA) prodrugs: synthesis, stability, antiviral activity, and in vivo transport studies. 2011

Valeria M Zakharova, and Michaela Serpi, and Ivan S Krylov, and Larryn W Peterson, and Julie M Breitenbach, and Katherine Z Borysko, and John C Drach, and Mindy Collins, and John M Hilfinger, and Boris A Kashemirov, and Charles E McKenna
Department of Chemistry, University of Southern California, Los Angeles, California 90089-0744, USA.

Eight novel single amino acid (6-11) and dipeptide (12, 13) tyrosine P-O esters of cyclic cidofovir ((S)-cHPMPC, 4) and its cyclic adenine analogue ((S)-cHPMPA, 3) were synthesized and evaluated as prodrugs. In vitro IC(50) values for the prodrugs (<0.1-50 μM) vs vaccinia, cowpox, human cytomegalovirus, and herpes simplex type 1 virus were compared to those for the parent drugs ((S)-HPMPC, 2; (S)-HPMPA, 1; IC(50) 0.3-35 μM); there was no cytoxicity with KB or HFF cells at ≤100 μM. The prodrugs exhibited a wide range of half-lives in rat intestinal homogenate at pH 6.5 (<30-1732 min) with differences of 3-10× between phostonate diastereomers. The tyrosine alkylamide derivatives of 3 and 4 were the most stable. (l)-Tyr-NH-i-Bu cHPMPA (11) was converted in rat or mouse plasma solely to two active metabolites and had significantly enhanced oral bioavailability vs parent drug 1 in a mouse model (39% vs <5%).

UI MeSH Term Description Entries
D008956 Models, Chemical Theoretical representations that simulate the behavior or activity of chemical processes or phenomena; includes the use of mathematical equations, computers, and other electronic equipment. Chemical Models,Chemical Model,Model, Chemical
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003587 Cytomegalovirus A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS. Herpesvirus 5, Human,Human Herpesvirus 5,Salivary Gland Viruses,HHV 5,Herpesvirus 5 (beta), Human,Cytomegaloviruses,Salivary Gland Virus,Virus, Salivary Gland,Viruses, Salivary Gland
D003596 Cytosine A pyrimidine base that is a fundamental unit of nucleic acids.
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077404 Cidofovir An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS. 1-((3-Hydroxy-2-phosphonylmethoxy)propyl)cytosine,1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine,Cidofovir Anhydrous,Cidofovir Sodium,Cidofovir, (+-)-isomer,Cidofovir, (R)-isomer,Cidofovir, Sodium Salt,GS 504,GS-504,HPMPC,Vistide,GS504
D000225 Adenine A purine base and a fundamental unit of ADENINE NUCLEOTIDES. Vitamin B 4,4, Vitamin B,B 4, Vitamin

Related Publications

Valeria M Zakharova, and Michaela Serpi, and Ivan S Krylov, and Larryn W Peterson, and Julie M Breitenbach, and Katherine Z Borysko, and John C Drach, and Mindy Collins, and John M Hilfinger, and Boris A Kashemirov, and Charles E McKenna
November 2007, Journal of medicinal chemistry,
Valeria M Zakharova, and Michaela Serpi, and Ivan S Krylov, and Larryn W Peterson, and Julie M Breitenbach, and Katherine Z Borysko, and John C Drach, and Mindy Collins, and John M Hilfinger, and Boris A Kashemirov, and Charles E McKenna
March 2007, Journal of medicinal chemistry,
Valeria M Zakharova, and Michaela Serpi, and Ivan S Krylov, and Larryn W Peterson, and Julie M Breitenbach, and Katherine Z Borysko, and John C Drach, and Mindy Collins, and John M Hilfinger, and Boris A Kashemirov, and Charles E McKenna
April 2018, ACS medicinal chemistry letters,
Valeria M Zakharova, and Michaela Serpi, and Ivan S Krylov, and Larryn W Peterson, and Julie M Breitenbach, and Katherine Z Borysko, and John C Drach, and Mindy Collins, and John M Hilfinger, and Boris A Kashemirov, and Charles E McKenna
January 1990, Advances in experimental medicine and biology,
Valeria M Zakharova, and Michaela Serpi, and Ivan S Krylov, and Larryn W Peterson, and Julie M Breitenbach, and Katherine Z Borysko, and John C Drach, and Mindy Collins, and John M Hilfinger, and Boris A Kashemirov, and Charles E McKenna
May 2011, Bioorganic & medicinal chemistry,
Valeria M Zakharova, and Michaela Serpi, and Ivan S Krylov, and Larryn W Peterson, and Julie M Breitenbach, and Katherine Z Borysko, and John C Drach, and Mindy Collins, and John M Hilfinger, and Boris A Kashemirov, and Charles E McKenna
July 1989, Journal of medicinal chemistry,
Valeria M Zakharova, and Michaela Serpi, and Ivan S Krylov, and Larryn W Peterson, and Julie M Breitenbach, and Katherine Z Borysko, and John C Drach, and Mindy Collins, and John M Hilfinger, and Boris A Kashemirov, and Charles E McKenna
December 2003, Antimicrobial agents and chemotherapy,
Valeria M Zakharova, and Michaela Serpi, and Ivan S Krylov, and Larryn W Peterson, and Julie M Breitenbach, and Katherine Z Borysko, and John C Drach, and Mindy Collins, and John M Hilfinger, and Boris A Kashemirov, and Charles E McKenna
November 2012, Antiviral research,
Valeria M Zakharova, and Michaela Serpi, and Ivan S Krylov, and Larryn W Peterson, and Julie M Breitenbach, and Katherine Z Borysko, and John C Drach, and Mindy Collins, and John M Hilfinger, and Boris A Kashemirov, and Charles E McKenna
October 2008, Biochemical pharmacology,
Valeria M Zakharova, and Michaela Serpi, and Ivan S Krylov, and Larryn W Peterson, and Julie M Breitenbach, and Katherine Z Borysko, and John C Drach, and Mindy Collins, and John M Hilfinger, and Boris A Kashemirov, and Charles E McKenna
December 2006, Journal of medicinal chemistry,
Copied contents to your clipboard!